Head-to-head evidence
Budesonide (targeted-release) vs Relacorilant (Lifyorli)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Glucocorticoid receptor · full Chronic Kidney Disease pipeline
Budesonide (targeted-release) · TARPEYO / Nefecon
Marketed by Asahi Kasei Corporation and partners
NCT06922305 · Phase 1 · completed
This was a randomized crossover study against two approved active comparators, but it was open-label and its endpoints were blood drug-level measurements rather than any measure of clinical benefit. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07030894 (registry estimate)
Relacorilant (Lifyorli)
Marketed by Corcept Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budesonide (targeted-release)'s landscape · Relacorilant (Lifyorli)'s landscape